Form 4: EyePoint CMO Sells Shares Under 10b5-1 Plan

EyePoint Pharmaceuticals' Chief Medical Officer, Ramiro Ribeiro, sold 2,722 shares of common stock for approximately $31,595 under a pre-arranged trading plan.

Summary

• Ramiro Ribeiro, Chief Medical Officer of EyePoint Pharmaceuticals, Inc. (EYPT), reported a sale of common stock.
• The transaction involved 2,722 shares of common stock.
• The shares were sold on November 11, 2025, at a weighted average price of $11.61 per share.
• The total value of the sale was approximately $31,595.02 (2,722 shares * $11.61/share).
• The sale was executed pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• The shares were originally acquired on January 31, 2025, through EyePoint's 2019 Employee Stock Purchase Plan.
• The sales occurred in multiple transactions with prices ranging from $11.30 to $11.75.

Sentiment

Score: 5

Explanation: A neutral score. While insider selling can sometimes be viewed negatively, this transaction is relatively small, pre-planned under a 10b5-1 plan, and likely related to personal financial management or tax planning rather than a signal about the company's future prospects.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors as it might suggest a lack of confidence, although this is a relatively small transaction.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing reports an individual insider transaction and does not provide information related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Minor impact. The sale is small and pre-planned, so it's unlikely to signal significant changes in company prospects. However, some investors might view any insider selling with caution.

Key Dates

Recommendation

This Form 4 filing reports a routine, pre-scheduled sale of a relatively small number of shares by a Chief Medical Officer under a 10b5-1 plan. Such transactions are typically for personal financial management and do not usually indicate a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this filing. Investors should continue to monitor broader company performance and industry trends.

Keywords

EyePoint Pharmaceuticals, EYPT, Ramiro Ribeiro, Chief Medical Officer, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Employee Stock Purchase Plan, Pharmaceuticals